KalVista Pharmaceuticals (STU:4XC1) Scaled Net Operating Assets : 0.14 (As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

KalVista Pharmaceuticals's operating assets for the quarter that ended in Jan. 2024 was €35.24 Mil. KalVista Pharmaceuticals's operating liabilities for the quarter that ended in Jan. 2024 was €16.47 Mil. KalVista Pharmaceuticals's Total Assets for the quarter that ended in Oct. 2023 was €131.39 Mil. Therefore, KalVista Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Jan. 2024 was 0.14.

KalVista Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for KalVista Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Scaled Net Operating Assets Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.07

0.16

0.14

0.11

0.10

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.12	0.10	0.13	0.12	0.14

Competitive Comparison of KalVista Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, KalVista Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Scaled Net Operating Assets falls into.

KalVista Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

KalVista Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Apr. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Apr. 2023 )
=	(Operating Assets (A: Apr. 2023 )	-	Operating Liabilities (A: Apr. 2023 ))	/	Total Assets (A: Apr. 2022 )
=	(30.85	-	12.718)	/	188.793
=	0.10

where

	Operating Assets		(A: Apr. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	167.08	-	136.23
=	30.85

	Operating Liabilities		(A: Apr. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	20.225	-	6.516	-	0.991
=	12.718

KalVista Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jan. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jan. 2024 )
=	(Operating Assets (Q: Jan. 2024 )	-	Operating Liabilities (Q: Jan. 2024 ))	/	Total Assets (Q: Oct. 2023 )
=	(35.235	-	16.469)	/	131.39
=	0.14

where

	Operating Assets		(Q: Jan. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	104.623	-	69.388
=	35.235

	Operating Liabilities		(Q: Jan. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	23.303	-	5.744	-	1.09
=	16.469

KalVista Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines